Silexion Therapeutics (NASDAQ:SLXN) Issues Quarterly Earnings Results

Silexion Therapeutics (NASDAQ:SLXN) released its quarterly earnings results on Friday. The company reported ($5.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($21.20) by $16.03, FiscalAI reports.

Silexion Therapeutics Price Performance

NASDAQ:SLXN traded down $0.04 during trading hours on Friday, reaching $0.42. 1,001,454 shares of the stock were exchanged, compared to its average volume of 492,483. Silexion Therapeutics has a twelve month low of $0.37 and a twelve month high of $80.00. The stock has a market cap of $176,484.00, a PE ratio of -0.01 and a beta of -0.25. The firm has a 50 day moving average of $2.42 and a 200 day moving average of $8.52.

Analyst Upgrades and Downgrades

SLXN has been the subject of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Monday, June 15th. Maxim Group cut Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.